Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,117 across all filing types
Latest filing 2020-06-19 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
西部证券股份有限公司关于公司使用部分闲置募集资金暂时补充流动资金的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (西部证券股份有限公司) regarding the use of idle raised funds by 珠海赛隆药业股份有限公司 to temporarily supplement working capital. It references regulatory guidelines related to the management and use of raised funds, board and supervisory approvals, independent directors' opinions, and compliance with relevant securities regulations. The document includes detailed descriptions of the raised funds usage, approvals, and compliance checks but does not contain financial statements or comprehensive financial performance data. It is a regulatory compliance and verification report related to fundraising usage rather than a financial report or earnings release. The document length is 3811 characters, which is relatively short and focused on a specific compliance verification. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2020-06-19 Chinese
关于使用部分闲置募集资金暂时补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhuhai Sailong Pharmaceutical Co., Ltd. regarding the use of part of idle raised funds to temporarily supplement working capital. It details the board meeting resolutions, the amount of funds involved, compliance with regulatory guidelines, and opinions from independent directors, the supervisory board, and the sponsor institution. The document does not contain financial statements or detailed financial performance data but rather focuses on the use and management of raised capital funds. It is a regulatory announcement about capital usage rather than a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 4170 characters, which is consistent with an announcement rather than a full report.
2020-06-19 Chinese
关于召开2020年第四次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2020 fourth extraordinary general meeting of shareholders for Zhuhai Sailong Pharmaceutical Co., Ltd. It includes details about the meeting date, location, agenda items, voting procedures, and proxy forms. It does not contain financial statements or results but is an announcement related to a shareholders' meeting. This fits the definition of a Proxy Solicitation & Information Statement (PSI), as it provides materials sent to shareholders to inform and request votes for the meeting.
2020-06-19 Chinese
关于为全资子公司申请银行授信提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Zhuhai Sailong Pharmaceutical Co., Ltd. regarding the provision of guarantees for bank credit applications by its wholly-owned subsidiary. It details the credit amounts, banks involved, the subsidiary's financial status, and the board and supervisory opinions. The document is a formal disclosure about financing support and guarantees, not a financial report or earnings release. It does not contain financial statements or detailed financial analysis but rather an update on capital/financing activities related to bank credit guarantees. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 3013 characters, which is consistent with an announcement rather than a full report.
2020-06-19 Chinese
独立董事关于公司第二届董事会第二十五次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on specific board meeting matters, including the use of idle raised funds and guarantees for a subsidiary's bank credit application. It references compliance with regulatory guidelines and company procedures but does not contain financial statements or detailed financial data. The document is a formal opinion related to board decisions rather than a full report or announcement of voting results. It fits best under Board/Management Information (MANG) as it concerns board meeting matters and independent directors' opinions on company governance issues.
2020-06-19 Chinese
关于归还暂时补充流动资金的闲置募集资金的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (644 characters) regarding the return of temporarily used idle raised funds to the company's dedicated fundraising account. It references a previous board resolution and provides an update on the status of the funds. There are no financial statements or detailed financial data included. The document is an announcement about the status of capital usage and return, not a full financial report or detailed capital change filing. It fits best under Capital/Financing Update (CAP) as it relates to the use and return of raised funds for liquidity purposes.
2020-06-16 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.